{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:49:04Z","timestamp":1791028144346,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.prp.2024.155803","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:29:50Z","timestamp":1736040590000},"page":"155803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["BRCA1 and BRCA2 mutations testing in prostate cancer: Detection in formalin fixed paraffin embedded (FFPE) and blood samples"],"prefix":"10.1016","volume":"266","author":[{"given":"Giuseppa","family":"Zannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-3184","authenticated-orcid":false,"given":"Renato","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zito Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2024.155803_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.prp.2024.155803_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6 1","key":"10.1016\/j.prp.2024.155803_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2003.10.013","article-title":"Epidemiology of prostate cancer","volume":"62","author":"Crawford","year":"2003","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.prp.2024.155803_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2024.155803_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1200\/JCO.2007.13.1490","volume":"26","author":"Ulmert","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155803_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/jpm14030287","article-title":"The application of radiomics and AI to molecular imaging for prostate cancer","volume":"14","author":"Tapper","year":"2024","journal-title":"J. Pers. Med"},{"issue":"4","key":"10.1016\/j.prp.2024.155803_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.prp.2024.155803_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094786","article-title":"Androgen receptor gene pathway upregulation and radiation resistance in oligometastatic prostate cancer","volume":"23","author":"Saxby","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.prp.2024.155803_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2024.155803_bib10","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference","author":"Gillessen","year":"2019","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.prp.2024.155803_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.prp.2024.155803_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/diagnostics10080549","article-title":"An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer","volume":"10","author":"Saxby","year":"2020","journal-title":"Diagnostics\u00a0(Basel)"},{"key":"10.1016\/j.prp.2024.155803_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154336","article-title":"Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types","volume":"243","author":"Zannini","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"4","key":"10.1016\/j.prp.2024.155803_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"issue":"23","key":"10.1016\/j.prp.2024.155803_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155803_bib16","unstructured":"Drug Approvals and Databases. U.S. Food and Drug Administration Web site. Available: \u3008https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases\u3009 [Accessed 29 Mar 2024]."},{"issue":"40","key":"10.1016\/j.prp.2024.155803_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.prp.2024.155803_bib18","first-page":"862","article-title":"BRCA genes: BRCA 1 and BRCA 2","volume":"23","author":"Varol","year":"2018","journal-title":"J. BUON"},{"key":"10.1016\/j.prp.2024.155803_bib19","article-title":"BRCA1- and BRCA2-associated hereditary breast and ovarian cancer","author":"Petrucelli","year":"2022","journal-title":"GeneReviews"},{"issue":"3","key":"10.1016\/j.prp.2024.155803_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265387","article-title":"Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations","volume":"17","author":"Annoni","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.prp.2024.155803_bib21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jamaoncol.2020.2134","article-title":"Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"6","author":"Silvestri","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155803_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14728222.2021.1951226","article-title":"Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology","volume":"25","author":"Boussios","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"9","key":"10.1016\/j.prp.2024.155803_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2024.155803_bib24","first-page":"3299","article-title":"Role for ATM in DNA damage-induced phosphorylation of BRCA1","volume":"60","author":"Gatei","year":"2000","journal-title":"Cancer Res."},{"issue":"5182","key":"10.1016\/j.prp.2024.155803_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"58","key":"10.1016\/j.prp.2024.155803_bib26","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1038\/sj.onc.1206176","article-title":"Homologous repair of DNA damage and tumorigenesis: the BRCA connection","volume":"21","author":"Jasin","year":"2002","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.prp.2024.155803_bib27","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.prp.2024.155803_bib28","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155803_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"issue":"14","key":"10.1016\/j.prp.2024.155803_bib30","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155803_bib31","unstructured":"Catalogue of Somatic Mutations in Cancer (COSMIC) database. Available: \u3008https:\/\/cancer.sanger.ac.uk\/cosmic\u3009 [Accessed 18 Mar 2024]."},{"key":"10.1016\/j.prp.2024.155803_bib32","unstructured":"ENIGMA. Available: \u3008https:\/\/enigmaconsortium.org\/library\/general-documents\/enigma-classification-criteria\/\u3009 [Accessed 18 Mar 2024]."},{"key":"10.1016\/j.prp.2024.155803_bib33","unstructured":"Aiom Guidelines: recommendations for implementing BRCA testing. Available at: \u3008https:\/\/www.fondazioneaiom.it\/raccomandazioni-per-limplementazione-del-test-brca-predittivo-e-preventivo-nei-tumori-della-mammella-dellovaio-del-pancreas-e-della-prostata\/\u3009 [Accessed 18 Mar 2024]."},{"issue":"12","key":"10.1016\/j.prp.2024.155803_bib34","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of variant reclassification following hereditary cancer genetic testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"issue":"39","key":"10.1016\/j.prp.2024.155803_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/EDBK_238977","article-title":"The role of BRCA testing in hereditary pancreatic and prostate cancer families","author":"Pilarski","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"11","key":"10.1016\/j.prp.2024.155803_bib36","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155803_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.prp.2024.155803_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3322\/caac.21720","article-title":"Genetic testing in prostate cancer management: considerations informing primary care","volume":"72","author":"Giri","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.prp.2024.155803_bib39","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur. Urol."},{"issue":"14","key":"10.1016\/j.prp.2024.155803_bib40","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pros.23219","article-title":"A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling","volume":"76","author":"Cheng","year":"2016","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.prp.2024.155803_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04897-x","article-title":"Mutations in BRCA2 and taxane resistance in prostate cancer","volume":"7","author":"Nientiedt","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.prp.2024.155803_bib42","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-019-02393-x","article-title":"The BRCA2 mutation status shapes the immune phenotype of prostate cancer","volume":"68","author":"Jenzer","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2024.155803_bib43","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1200\/PO.19.00388","article-title":"Genomic profiles of de novo high- and low-volume metastatic prostate cancer: results from a 2-stage feasibility and prevalence study in the STAMPEDE trial","volume":"4","author":"Gilson","year":"2020","journal-title":"JCO Precis Oncol."},{"issue":"21","key":"10.1016\/j.prp.2024.155803_bib44","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1038\/s41388-020-1280-x","article-title":"Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians","volume":"39","author":"Yadav","year":"2020","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.prp.2024.155803_bib45","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","article-title":"BRCA mutations and risk of prostate cancer in Ashkenazi Jews","volume":"10","author":"Kirchhoff","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2024.155803_bib46","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/sj.bjc.6605822","article-title":"Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis","volume":"103","author":"Edwards","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2024.155803_bib47","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.prp.2024.155803_bib48","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/pros.22860","article-title":"Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations","volume":"74","author":"Maier","year":"2014","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.prp.2024.155803_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.20892\/j.issn.2095-3941.2020.0481","article-title":"BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees","volume":"18","author":"Cortesi","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"6","key":"10.1016\/j.prp.2024.155803_bib50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2021.09.029","article-title":"Association of inherited mutations in DNA repair genes with localized prostate cancer","volume":"81","author":"Lee","year":"2022","journal-title":"Eur. Urol."},{"issue":"24","key":"10.1016\/j.prp.2024.155803_bib51","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.prp.2024.155803_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189783","article-title":"Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic","volume":"22","author":"Ghose","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.prp.2024.155803_bib53","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.molonc.2015.07.002","article-title":"Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses","volume":"9","author":"Hertz","year":"2015","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2024.155803_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju401","article-title":"Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies","volume":"107","author":"Goetz","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.prp.2024.155803_bib55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/FPC.0b013e32833deb16","article-title":"A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens","volume":"20","author":"Horn","year":"2010","journal-title":"Pharm. Genom."},{"issue":"8","key":"10.1016\/j.prp.2024.155803_bib56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00008571-200308000-00008","article-title":"Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples","volume":"13","author":"Rae","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"17","key":"10.1016\/j.prp.2024.155803_bib57","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jnci\/djt204","article-title":"Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA","volume":"105","author":"Rae","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"16","key":"10.1016\/j.prp.2024.155803_bib58","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2217\/pgs.13.169","article-title":"Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples","volume":"14","author":"van Huis-Tanja","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.prp.2024.155803_bib59","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824007143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824007143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:33:43Z","timestamp":1739273623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824007143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":59,"alternative-id":["S0344033824007143"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155803","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA1 and BRCA2 mutations testing in prostate cancer: Detection in formalin fixed paraffin embedded (FFPE) and blood samples","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155803"}}